Dr. Samuel Grossman is a doctor of clinical pharmacy and a diabetes educator at the Department of Veterans Affairs New York Harbor Health Care System. Read My Bio
Dr. Samuel Grossman is a doctor of clinical pharmacy and a diabetes educator at the Department of Veterans Affairs New York Harbor Health Care System. He also serves as the President and clinical coordinator of Diabetes Care On-The-Go Inc., a diabetes education center that serves the diabetes population of NY and NJ. In addition, Dr. Grossman serves as an Adjunct Associate Professor at Hunter-Bellevue School of Nursing of the City University of New York and a Clinical Assistant Professor of Pharmacy at Arnold & Marie Schwartz College of Pharmacy of Long Island University. He is also the Advocacy chair and a member of the New Jersey Community Leadership Board for the American Diabetes Association. Dr. Grossman, the recipient of the 2012 "Diabetes Educator of the Year" award from AADE New Jersey Coordinating body for work done to promote diabetes awareness in the community, has been published in numerous publications in the area of diabetes and has given many presentations nationwide about this topic.
Samuel's Latest Posts
-
FDA Approves Two Insulins
Tuesday, October 06, 2015
The Food and Drug Administration (FDA) surprisingly approved insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg) 70/30. Pharmacist and CDE Sam Grossman discusses some of the clinical trial findings for the medicines and offers some clinical prescribing guidance.
-
Does a Popular Type 2 Medicine Create a B12 Deficiency?
Tuesday, September 15, 2015
Chronic usage of metformin, the first-line type 2 medicine, can cause vitamin B12 deficiencies in many people. Sam Grossman talks about what is in the medical literature about this topic and offers some advice to avoid a deficiency in this essential vitamin.
-
Jardiance and Heart Disease
Wednesday, September 02, 2015
A new study reports that Jardiance reduces the risk of acute cardiovascular episodes including heart attacks and strokes. Certified diabetes educator Sam Grossman looks at the study and provides analysis.
-
Statins: Risk Vs. Reward
Tuesday, August 11, 2015
Dr. Sam Grossman looks at statin use in people at risk for diabetes and discusses the risks versus the benefits.
-
7 Tips on Safety and Adherence to Medication on Vacation
Friday, July 24, 2015
Poor adherence to medical treatment is widespread and well recognized. Here are seven tips to help you adhere to your proper medication usage while on vacation.
-
No Increased Heart Risks for DPP-4 inhibitors
Friday, July 17, 2015
According to a study that was published in the New England Journal of Medicine, this class of drugs did not increase the risk for cardiovascular events, which was previously discussed and a concern in the medical community.
-
Who Can Benefit from the New U-200 Insulin?
Monday, June 22, 2015
Sam Grossman provides some information on the recently approved 200 unit/mL formulation of Eli Lilly and Company’s pre-filled pen containing insulin lispro (Humalog U-200 KwikPen).
-
Linking a Type 2 Drug to Too Much Acid in the Blood
Monday, June 08, 2015
The U.S. Food and Drug Administration (FDA) recently announced that sodium-glucose cotransporter-2 (SGLT2) inhibitors may be linked to cases of increased levels of acid in the blood. Sam Grossman talks about the FDA's reporting on this subject.
-
Is a Cheaper, Off-Label Drug Better for Diabetic Eye Disease?
Thursday, May 21, 2015
Genentech's drug Avastin is used to treat cancer, but has also been used off-label for treatment of eye disease including diabetic retinopathy (DR). Sam Grossman discusses some of the studies' findings of this medicine and whether people with DR may want to inquire with their healthcare providers about it.
-
New Heart Concerns for Existing Class of Type 2 Medications
Monday, April 27, 2015
An FDA Panel recommends new safety information on DPP-4 inhibitors Onglyza and Nesina. Sam Grossman reviews this news and how it may affect marketing and prescribing of the medications.
-
A New Long-Acting Insulin Option
Friday, April 17, 2015
Sanofi's recently approved insulin, Toujeo, is 300u/ml and offers clinicians and people with diabetes who have glycemic control issues another long-acting insulin. Sam Grossman discusses some of the studies' findings.
-
Will a Combination Drug Revolutionize Diabetes Therapy?
Saturday, March 28, 2015
Glyxambi is a new type 2 drug and is the first diabetes treatment in the U.S. to combine the dual mechanisms of action of a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor in a once-daily tablet. Pharmacist and CDE Sam Grossman reviews the drug.
-
A New Treatment for Diabetic Retinopathy
Wednesday, March 11, 2015
The FDA recently approved Lucentis for use of diabetic retinopathy. Pharmacist and certified diabetes educator Sam Grossman talks about the clinical trial results for the new drug and considerations of how people with the complication may want to consider talking to their provider about it.
-
Afrezza: Will it revolutionize insulin therapy?
Friday, February 13, 2015
The FDA approved the inhaled insulin, Afrezza, last summer, and it will likely undergo a massive marketing campaign to providers and possibly to people with diabetes directly. Here is some important clinical trial information about the medicine and how it is indicated for use in patients.
-
A New Treatment Option for Weight Management
Friday, January 09, 2015
Saxenda was recently approved by the FDA as a treatment for weight management.
-
A New Basal Insulin With Lasting Power
Thursday, December 04, 2014
Novo Nordisk's newer insulin with an ultra-long duration of action is being used internationally already. Dr. Sam Grossman explores this unique medicine and a potential timetable for when Novo will submit requested data to the FDA.
-
FDA Approves Xigduo XR
Thursday, November 20, 2014
AstraZeneca announced recently that the US Food and Drug Administration has approved once-daily Xigduo XR (dapagliflozin and metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes.
-
Combined Insulin Therapy Offers Benefits
Thursday, November 06, 2014
Novo Nordisk's Ryzodeg is a new opportunity for patients to improve insulin therapy by combining basal and bolus insulin with fewer shots as an added bonus.
-
A New Weekly GLP-1 Agonist for Type 2 Patients
Thursday, October 23, 2014
Eli Lily's Trulicity is a once weekly glucagon-like peptide-1 (GLP-1) receptor agonist that was recently FDA approved. Read why this medication might be a worthy alternative GLP-1 agonist to improve patients' fasting glucose levels.
-
A New Insulin is on the Way
Friday, September 19, 2014
The FDA recently granted tentative approval for Basaglar (insulin glargine injection) which was developed in partnership between Eli Lilly and Company and Boehringer Ingelheim.
-
Empagliflozin: a Dim or a Shining Star in the Treatment of Type 2?
Wednesday, August 13, 2014
This sodium glucose cotransporter 2 (SGLT2) inhibitor indicated for type 2s was recently FDA approved. What may truly make this medication standout is the efforts to combine this with a dipeptidyl peptidase-4 (DPP-4) inhibitor.
-
A Clinical Look at the New FDA Approved Inhaled Insulin
Wednesday, July 16, 2014
Mannkind's Afrezza was recently approved by the Food and Drug Administration (FDA). Dr. Sam Grossman discusses some of the studies of this new inhaled formulation of insulin that is indicated for patients with type 1 or type 2 diabetes.
-
A DPP-4 inhibitor Shows Promising Data
Monday, June 30, 2014
Dr. Sam Grossman discusses positive study results for Merck's Januvia (Sitagliptin) that were presented at the recent ADA Scientific Sessions.
